Wednesday, April 22

Browsing: CLLSLL

Survivors

Pirtobrutinib Triplet Boosts PFS in Relapsed/Refractory CLL/SLL Trial

By NewsCancerApril 14, 20260

Adding pirtobrutinib (Jaypirca) to venetoclax (Venclexta) and rituximab (Rituxan) significantly prolonged progression-free survival (PFS) vs venetoclax/rituximab alone among patients with…

Treatments

Acalabrutinib Approval Offers Time-Limited Approach in CLL/SLL

By NewsCancerMarch 13, 20260

In a conversation with CancerNetwork® at the Columbia University Irving Cancer Research Center, Nicole Lamanna, MD, highlighted the implications of…

Support

FDA Approves Acalabrutinib Combo in Frontline CLL/SLL

By NewsCancerFebruary 20, 20260

The FDA has approved fixed-duration acalabrutinib (Calquence) plus venetoclax (Venclecxta) as a first-line treatment for adults with chronic lymphocytic leukemia…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

Work, Money, & a Normal Life

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

Browsing: CLLSLL

Pirtobrutinib Triplet Boosts PFS in Relapsed/Refractory CLL/SLL Trial

Acalabrutinib Approval Offers Time-Limited Approach in CLL/SLL

FDA Approves Acalabrutinib Combo in Frontline CLL/SLL

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

Work, Money, & a Normal Life

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

Work, Money, & a Normal Life

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Latest Post

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

Work, Money, & a Normal Life

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

Subscribe to Updates

What's Hot

Browsing: CLLSLL